755 related articles for article (PubMed ID: 25905624)
41. Design of lipid-based formulations for oral administration of poorly water-soluble drugs: precipitation of drug after dispersion of formulations in aqueous solution.
Mohsin K; Long MA; Pouton CW
J Pharm Sci; 2009 Oct; 98(10):3582-95. PubMed ID: 19130605
[TBL] [Abstract][Full Text] [Related]
42. Lipid digestion as a trigger for supersaturation: evaluation of the impact of supersaturation stabilization on the in vitro and in vivo performance of self-emulsifying drug delivery systems.
Anby MU; Williams HD; McIntosh M; Benameur H; Edwards GA; Pouton CW; Porter CJ
Mol Pharm; 2012 Jul; 9(7):2063-79. PubMed ID: 22656917
[TBL] [Abstract][Full Text] [Related]
43. Lidocaine self-sacrificially improves the skin permeation of the acidic and poorly water-soluble drug etodolac via its transformation into an ionic liquid.
Miwa Y; Hamamoto H; Ishida T
Eur J Pharm Biopharm; 2016 May; 102():92-100. PubMed ID: 26945484
[TBL] [Abstract][Full Text] [Related]
44. Comparison across Three Hybrid Lipid-Based Drug Delivery Systems for Improving the Oral Absorption of the Poorly Water-Soluble Weak Base Cinnarizine.
Joyce P; Yasmin R; Bhatt A; Boyd BJ; Pham A; Prestidge CA
Mol Pharm; 2017 Nov; 14(11):4008-4018. PubMed ID: 28950059
[TBL] [Abstract][Full Text] [Related]
45. The novel formulation design of self-emulsifying drug delivery systems (SEDDS) type O/W microemulsion I: enhancing effects on oral bioavailability of poorly water soluble compounds in rats and beagle dogs.
Araya H; Nagao S; Tomita M; Hayashi M
Drug Metab Pharmacokinet; 2005 Aug; 20(4):244-56. PubMed ID: 16141604
[TBL] [Abstract][Full Text] [Related]
46. 'Stealth' lipid-based formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug.
Feeney OM; Williams HD; Pouton CW; Porter CJ
J Control Release; 2014 Oct; 192():219-27. PubMed ID: 25058571
[TBL] [Abstract][Full Text] [Related]
47. Assessment of cell viability and permeation enhancement in presence of lipid-based self-emulsifying drug delivery systems using Caco-2 cell model: Polysorbate 80 as the surfactant.
Bu P; Ji Y; Narayanan S; Dalrymple D; Cheng X; Serajuddin AT
Eur J Pharm Sci; 2017 Mar; 99():350-360. PubMed ID: 28024890
[TBL] [Abstract][Full Text] [Related]
48. Enhanced oral bioavailability of dexibuprofen by a novel solid self-emulsifying drug delivery system (SEDDS).
Balakrishnan P; Lee BJ; Oh DH; Kim JO; Hong MJ; Jee JP; Kim JA; Yoo BK; Woo JS; Yong CS; Choi HG
Eur J Pharm Biopharm; 2009 Aug; 72(3):539-45. PubMed ID: 19298857
[TBL] [Abstract][Full Text] [Related]
49. Formulation optimization of self-emulsifying preparations of puerarin through self-emulsifying performances evaluation in vitro and pharmacokinetic studies in vivo.
Quan DQ; Xu GX
Yao Xue Xue Bao; 2007 Aug; 42(8):886-91. PubMed ID: 17944241
[TBL] [Abstract][Full Text] [Related]
50. Lipid-based systems as a promising approach for enhancing the bioavailability of poorly water-soluble drugs.
Cerpnjak K; Zvonar A; Gašperlin M; Vrečer F
Acta Pharm; 2013 Dec; 63(4):427-45. PubMed ID: 24451070
[TBL] [Abstract][Full Text] [Related]
51. Studying the effect of lipid chain length on the precipitation of a poorly water soluble drug from self-emulsifying drug delivery system on dispersion into aqueous medium.
Prasad D; Chauhan H; Atef E
J Pharm Pharmacol; 2013 Aug; 65(8):1134-44. PubMed ID: 23837581
[TBL] [Abstract][Full Text] [Related]
52. Unlocking the full potential of lipid-based formulations using lipophilic salt/ionic liquid forms.
Williams HD; Ford L; Igonin A; Shan Z; Botti P; Morgen MM; Hu G; Pouton CW; Scammells PJ; Porter CJH; Benameur H
Adv Drug Deliv Rev; 2019 Mar; 142():75-90. PubMed ID: 31150666
[TBL] [Abstract][Full Text] [Related]
53. Formulation development of an albendazole self-emulsifying drug delivery system (SEDDS) with enhanced systemic exposure.
Meena AK; Sharma K; Kandaswamy M; Rajagopal S; Mullangi R
Acta Pharm; 2012 Dec; 62(4):563-80. PubMed ID: 24000442
[TBL] [Abstract][Full Text] [Related]
54. In vitro-in vivo evaluation of lipid based formulations of the CETP inhibitors CP-529,414 (torcetrapib) and CP-532,623.
McEvoy CL; Trevaskis NL; Edwards GA; Perlman ME; Ambler CM; Mack MC; Brockhurst B; Porter CJ
Eur J Pharm Biopharm; 2014 Nov; 88(3):973-85. PubMed ID: 25152213
[TBL] [Abstract][Full Text] [Related]
55. Development of solid SEDDS, VII: Effect of pore size of silica on drug release from adsorbed self-emulsifying lipid-based formulations.
Gumaste SG; Serajuddin ATM
Eur J Pharm Sci; 2017 Dec; 110():134-147. PubMed ID: 28506870
[TBL] [Abstract][Full Text] [Related]
56. Correlating in Vitro Solubilization and Supersaturation Profiles with in Vivo Exposure for Lipid Based Formulations of the CETP Inhibitor CP-532,623.
McEvoy CL; Trevaskis NL; Feeney OM; Edwards GA; Perlman ME; Ambler CM; Porter CJH
Mol Pharm; 2017 Dec; 14(12):4525-4538. PubMed ID: 29076741
[TBL] [Abstract][Full Text] [Related]
57. A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs.
Holm R; Jørgensen EB; Harborg M; Larsen R; Holm P; Müllertz A; Jacobsen J
Eur J Pharm Sci; 2011 Mar; 42(4):416-22. PubMed ID: 21256961
[TBL] [Abstract][Full Text] [Related]
58. Ionic Liquids: Promising Approach for Oral Drug Delivery.
Jiang L; Sun Y; Lu A; Wang X; Shi Y
Pharm Res; 2022 Oct; 39(10):2353-2365. PubMed ID: 35449344
[TBL] [Abstract][Full Text] [Related]
59. Comparison of in vitro tests at various levels of complexity for the prediction of in vivo performance of lipid-based formulations: case studies with fenofibrate.
Griffin BT; Kuentz M; Vertzoni M; Kostewicz ES; Fei Y; Faisal W; Stillhart C; O'Driscoll CM; Reppas C; Dressman JB
Eur J Pharm Biopharm; 2014 Apr; 86(3):427-37. PubMed ID: 24184675
[TBL] [Abstract][Full Text] [Related]
60. Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans.
Wasan EK; Bartlett K; Gershkovich P; Sivak O; Banno B; Wong Z; Gagnon J; Gates B; Leon CG; Wasan KM
Int J Pharm; 2009 May; 372(1-2):76-84. PubMed ID: 19236839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
